{"id":7821,"date":"2024-02-29T15:30:01","date_gmt":"2024-02-29T23:30:01","guid":{"rendered":"https:\/\/rakuten-med.com\/us\/?post_type=press_releases&p=7821"},"modified":"2024-03-06T19:07:55","modified_gmt":"2024-03-07T03:07:55","slug":"over-20-presentations-on-alluminox-treatment-photoimmunotherapy-at-international-conferences-in-2023","status":"publish","type":"press_releases","link":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2024\/02\/29\/7821\/","title":{"rendered":"Over 20 Presentations on Alluminox Treatment (Photoimmunotherapy) at International Conferences in 2023"},"content":{"rendered":"
\n
\n\t

Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox\u2122 platform, is pleased to announce that, during the year 2023, findings from preclinical studies, clinical trials, and real-world data on Alluminox treatment (photoimmunotherapy) have been presented at multiple international conferences. The 21 presentations are listed at the end of the press release.<\/span><\/p>\n

Mickey Mikitani, Co-CEO of Rakuten Medical, said, \u201cWitnessing the surge in findings on Alluminox treatment shared at prestigious conferences around the world fills me with immense pride. We would like to thank all the dedicated healthcare professionals worldwide who share their excitement for this innovative technology and the potential of the Alluminox\u2122 platform. Together with the medical community, we remain committed to advancing this treatment and shaping the future of patient care.\u201d<\/span><\/p>\n

ASP-1929 (Japanese product name: Akalux\u00ae IV Infusion 250 mg), the first drug developed on Rakuten Medical's proprietary Alluminox\u2122 platform, was approved for unresectable, locally advanced or recurrent head and neck cancer in Japan under the Sakigake Designation System and the Conditional Early Approval System in September 2020. With the increase in the number of treatment cases in the clinic, a range of findings on the Alluminox treatment have been reported, including treatment results and management of adverse events.\u00a0<\/span><\/p>\n

* Rakuten Medical\u2019s therapies based on Alluminox\u2122 platform are investigational outside of Japan.<\/span><\/em><\/p>\n

Significant progress was also made in clinical trial: <\/span>Promising early evaluation data on safety and efficacy were observed in the Phase 1b\/2 clinical trial<\/span><\/a> (ASP-1929-181 study \/ ClinicalTrials.gov Identifier: <\/span>NCT04305795<\/span><\/a>) of ASP-1929 photoimmunotherapy in combination with anti-PD-1 therapy presented at the American Head and Neck Society International Meeting (AHNS) in July 2023 in Canada. To further explore these data, <\/span>AI-based studies of biomarkers and drug uptake quantification in tumors<\/span><\/a> have been conducted in collaboration with Rakuten Institute of Technology, and the findings were presented at the Society for Immunotherapy of Cancer (SITC) in the United States in November 2023. Rakuten Medical is currently considering initiating a new pivotal clinical trial to further demonstrate and confirm the safety and efficacy of this combination therapy.<\/span><\/p>\n

In August 2023, Mikitani was invited as a keynote speaker at ASCO Breakthrough, which is organized in Asia by the American Society of Clinical Oncology (ASCO), the world's premier cancer society. In his keynote presentation, Mikitani recalled his first encounter with the innovative technology, photoimmunotherapy, and shared his hope and confidence in the potential of Rakuten Medical's Alluminox platform to contribute to the treatment of a variety of cancer types and stages in the future. The full recording of this keynote is available at the <\/span>ASCO Breakthrough website<\/span><\/a>, and a digest version (1:45) is available here:<\/span><\/p>\n<\/div>\n<\/div><\/div>